Bextra, Valdecoxib News

The Penang Medical Practitioners Society , the oldest medical organisation in Malaysia, will be holding a public forum on "Health Care Financing" on 15 June from 9.00am to 1.00pm at the Dewan Sri Pinang.

Posted: June 8th, 2008 by Steve Trinward Author: John Goodman here is a new book out on pharmaceuticals with a chapter by yours truly.

Gregory D. Curfman, M.D., Stephen Morrissey, Ph.D., George J. Annas, J.D., M.P.H., and Jeffrey M. Drazen, M.D. For many years, the editors of the Journal have relied on peer review to ensure the scientific ...

“Celecoxib seems especially protective, and given the relatively weak evidence (compared with other COX-2 inhibitors) of its being associated with cardiovascular complications, its use should be more strongly considered.”

Although all of the common strategies protect the upper gastrointestinal tract from the complications of nonsteroidal anti-inflammatory drugs , popular over-the-counter analgesics such as Motrin or Aleve , the ... via Reuters UK

Pfizer Inc has reached tentative deals with some patients who allege to have suffered heart attacks and strokes from taking the company's Celebrex and Bextra pain medicines, the Wall Street Journal said on ... via Reuters

“That wasn't so clear previously.”

CHICAGO - Doctors should prescribe the lowest doses of Celebrex possible in patients at high risk of heart problems, researchers who did a combined analysis of six studies of the Pfizer Inc pain ... via Reuters

ScienceNow reported: In a decision likely to be welcomed by editors everywhere, a federal judge in Chicago today [March 14] denied a drug company's efforts to obtain confidential peer-review documents from a ... via IPBiz

“Although her statements are quite dramatic, it is not unreasonable to believe that compelling production of peer review documents would compromise the process”

Posted on 03/14/2008 11:41:19 PM PDT by neverdem In a decision likely to be welcomed by editors everywhere, a federal judge in Chicago today denied a drug company's efforts to obtain confidential peer-review ... via Free Republic

“Pfizer has strict and extensive policies to ensure the appropriate retention of documents”

A former Pfizer Inc. district sales manager has been charged with obstruction of justice following an investigation of off-label uses of two of the company's prescription drugs. via The Day

“Scientific journals such as NEJM may have received manuscripts that contain exonerating data for Celebrex and Bextra which would be relevant for Pfizer's causation defence”

A multinational drugs company is trying to force a medical science journal to reveal the confidential statements made by the journal's expert reviewers in a test case that could undermine one of the central ... via The Independent

“They've shown better results than the standard treatments and, in the near-term at least, they won't have competition from generics. They will represent the lion's share of growth in the market.”

The rheumatoid arthritis treatment market, held back somewhat in recent years by generic competition and the withdrawal of Vioxx and Bextra, is rebounding due to the performance of biologic treatments. via Med Ad News

“They should also include concerns about non-CVD risks such as gastrointestinal bleeding, and other benefits, including improved quality of life resulting from decreases in impairment from musculoskeletal pain syndromes.”

Selective COX-2 inhibitors were believed to cause large cardiovascular disease risks , including heart attacks, strokes and deaths. via Newswise

Do you suffer from chronic joint pain? Have you seen a doctor and been given prescription medicine, but are weary of the nasty side effects? If so, you're not alone. via Associated Content

CONGERS - A pharmacist at the Kwik Aid Pharmacy in the hamlet has been fined $10,000 after a licensing board found that she tried to use false documents to get a refund from a drug manufacturer, according to ... via Journal News

“Today's announcement reinforces our previous advice COX-2s should be used after careful consideration of the risks and benefits and the lowest effective dose for the shortest duration of time.”

A PAINKILLER used by tens of thousands of arthritis sufferers in the UK has been withdrawn from the market over fears it leads to an increased risk of heart attacks and serious skin reactions. via The Scotsman

“Pain is a subjective experience”

The pain-relief market has become a big pain for big pharma, even as demographic trends show there's plenty of room for new business.

For an aging population living with arthritic pain, there's nothing new on the horizon. That helps explain some of the results in a recent report by Thomson Healthcare called "Vioxx or Bust: Pharma Market Still Needs Suitable Replacement."

The data firm looked at the void in the drug market after Merck (MRK) pulled its Vioxx pain treatment off the market in 2004. Read more

It is known that gastrointestinal complications from the use of nonsteroidal anti-inflammatory drugs are significantly reduced when also taking gastroprotective drugs such as a proton pump inhibitor or ... via About.com

Google AdWords is a very simple idea that's surprisingly little understood. On every page of Google search results, in your Gmail and your Froogle results, and more and more on the pages of other Web sites , ... via Seth's Blog

“The pro-industry culture and its decision-making hasn't changed.”

Ten years ago, two wildly popular obesity drugs were withdrawn from the market by their maker after being linked to thousands of cases of severe heart and lung damage and several deaths. via Seattle Times

“They wouldn't have had to make a settlement if they hadn't concealed things.”

With Friday's announcement of almost $5 billion to be paid out to those people claiming they were hurt by the now-withdrawn painkiller Vioxx, the drug's maker, Merck & Co., may have hoped to end the glare of ... via Drkoop.com